Eisai Co Ltd Spons A (ESALY) 64.9950 $ESALY Med
Post# of 273254
Posted On: 09/23/2016 5:14:11 AM
Eisai Co Ltd Spons A (ESALY) 64.9950 $ESALY
MediWound (MDWD) in Focus: Stock Moves 23.4% Higher
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:30AM CDT
MediWound Ltd. (MDWD) moved big last session, as its shares jumped over 23% on the day.
MDWD: 8.00 (+0.22)
KemPharm (KMPH) Looks Good: Stock Adds 9% in Session
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:25AM CDT
KemPharm, Inc. (KMPH) moved big last session, as its shares jumped a little over 9% on the day.
KMPH: 4.55 (+0.02)
Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 20.26 (+0.17), CORT: 6.49 (+0.27), PCRX: 37.52 (+0.71)
Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:55AM CDT
Jazz (JAZZ) updated its 2016 guidance to reflect the Celator acquisition and the modification in the calculation of non-GAAP income tax provision.
JAZZ: 126.65 (-2.16), CORT: 6.49 (+0.27), PCRX: 37.52 (+0.71)
Alcobra (ADHD) Looks Good: Stock Adds 14.4% in Session
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:25AM CDT
Alcobra Ltd. (ADHD) moved big last session, as its shares jumped over 14% on the day.
ADHD: 4.70 (-0.02)
Galectin Therapeutics (GALT) Jumps: Stock Rises 17.1%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:25AM CDT
Galectin Therapeutics, Inc. (GALT) moved big last session, as its shares jumped a little over 17% on the day.
GALT: 2.87 (+0.27)
Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 3.54 (+0.36), ARNA: 1.77 (-0.01), EXEL: 14.74 (unch)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:25AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) moved big last session, as its shares jumped almost 14% on the day.
BCRX: 4.76 (+0.07)
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 7.29 (-0.11)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 119.46 (+0.55), GILD: 81.52 (-0.18), PFE: 34.15 (-0.13), AMGN: 175.62 (+1.77), ABBV: 65.08 (+0.98), RDY: 47.70 (+0.91), AVXS: 42.50 (-1.76), NVS: 82.03 (+0.51)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 26.44 (-0.01), CLSN: 1.24 (unch), JAZZ: 126.65 (-2.16)
Halozyme Raises Funds to Support Ongoing Oncology Studies
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 3:55PM CST
Halozyme (HALO) announced that it has entered into a $150 million credit agreement secured by future royalties from Enhanze products, which Halozyme is entitled to receive from its collaborations with Roche and Baxalta, Inc.
HALO: 12.40 (-0.03), BXLT: 46.02 (-0.18)
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Arpita Dutt - Zacks Investment Research - Tue Dec 01, 3:32PM CST
Arena (ARNA) is looking to get a once-daily formulation of its chronic weight management treatment approved in the U.S.
ACHN: 8.44 (+0.34), BXLT: 46.02 (-0.18), ARNA: 1.77 (-0.01)
Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 9:34AM CST
Arena (ARNA) is looking to cut costs and improve efficiency through a restructuring plan.
ACHN: 8.44 (+0.34), BXLT: 46.02 (-0.18), ARNA: 1.77 (-0.01)
Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2015 adjusted earnings of $2.16 per share, up 7.5% year over year.
JAZZ: 126.65 (-2.16), TEVA: 51.23 (+0.75), CNCE: 10.46 (+0.04)
MediWound (MDWD) in Focus: Stock Moves 23.4% Higher
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:30AM CDT
MediWound Ltd. (MDWD) moved big last session, as its shares jumped over 23% on the day.
MDWD: 8.00 (+0.22)
KemPharm (KMPH) Looks Good: Stock Adds 9% in Session
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:25AM CDT
KemPharm, Inc. (KMPH) moved big last session, as its shares jumped a little over 9% on the day.
KMPH: 4.55 (+0.02)
Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 20.26 (+0.17), CORT: 6.49 (+0.27), PCRX: 37.52 (+0.71)
Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:55AM CDT
Jazz (JAZZ) updated its 2016 guidance to reflect the Celator acquisition and the modification in the calculation of non-GAAP income tax provision.
JAZZ: 126.65 (-2.16), CORT: 6.49 (+0.27), PCRX: 37.52 (+0.71)
Alcobra (ADHD) Looks Good: Stock Adds 14.4% in Session
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:25AM CDT
Alcobra Ltd. (ADHD) moved big last session, as its shares jumped over 14% on the day.
ADHD: 4.70 (-0.02)
Galectin Therapeutics (GALT) Jumps: Stock Rises 17.1%
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:25AM CDT
Galectin Therapeutics, Inc. (GALT) moved big last session, as its shares jumped a little over 17% on the day.
GALT: 2.87 (+0.27)
Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Mon Aug 01, 7:56AM CDT
Will an improvement in Belviq's performance help Arena (ARNA) deliver a surprise in Q2?
FATE: 3.54 (+0.36), ARNA: 1.77 (-0.01), EXEL: 14.74 (unch)
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 13.7%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:25AM CDT
BioCryst Pharmaceuticals, Inc. (BCRX) moved big last session, as its shares jumped almost 14% on the day.
BCRX: 4.76 (+0.07)
GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 7.29 (-0.11)
Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 119.46 (+0.55), GILD: 81.52 (-0.18), PFE: 34.15 (-0.13), AMGN: 175.62 (+1.77), ABBV: 65.08 (+0.98), RDY: 47.70 (+0.91), AVXS: 42.50 (-1.76), NVS: 82.03 (+0.51)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 26.44 (-0.01), CLSN: 1.24 (unch), JAZZ: 126.65 (-2.16)
Halozyme Raises Funds to Support Ongoing Oncology Studies
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 3:55PM CST
Halozyme (HALO) announced that it has entered into a $150 million credit agreement secured by future royalties from Enhanze products, which Halozyme is entitled to receive from its collaborations with Roche and Baxalta, Inc.
HALO: 12.40 (-0.03), BXLT: 46.02 (-0.18)
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Arpita Dutt - Zacks Investment Research - Tue Dec 01, 3:32PM CST
Arena (ARNA) is looking to get a once-daily formulation of its chronic weight management treatment approved in the U.S.
ACHN: 8.44 (+0.34), BXLT: 46.02 (-0.18), ARNA: 1.77 (-0.01)
Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 9:34AM CST
Arena (ARNA) is looking to cut costs and improve efficiency through a restructuring plan.
ACHN: 8.44 (+0.34), BXLT: 46.02 (-0.18), ARNA: 1.77 (-0.01)
Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2015 adjusted earnings of $2.16 per share, up 7.5% year over year.
JAZZ: 126.65 (-2.16), TEVA: 51.23 (+0.75), CNCE: 10.46 (+0.04)
(0)
(0)Scroll down for more posts ▼